Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PACB.O
stocks logo

PACB.O

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
41.65M
+6.18%
-0.152
-1620%
41.31M
+11.19%
-0.144
-90%
43.57M
+9.57%
-0.132
-5.71%
Estimates Revision
The market is revising Downward the revenue expectations for Pacific Biosciences of California, Inc. (PACB) for FY2025, with the revenue forecasts being adjusted by -1.82% over the past three months. During the same period, the stock price has changed by 18.05%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.82%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.3%
In Past 3 Month
Stock Price
Go Up
up Image
+18.05%
In Past 3 Month
Wall Street analysts forecast PACB.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB.O is 2.30 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast PACB.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB.O is 2.30 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.570
sliders
Low
1.50
Averages
2.30
High
3.00
Current: 1.570
sliders
Low
1.50
Averages
2.30
High
3.00
Piper Sandler
Neutral
maintain
$2
2025-11-11
Reason
Piper Sandler
Price Target
$2
2025-11-11
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on PacBio to $2 from $1.50 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.
Stephens
Overweight
maintain
$2
2025-11-10
Reason
Stephens
Price Target
$2
2025-11-10
maintain
Overweight
Reason
Stephens raised the firm's price target on PacBio to $2 from $1.80 and keeps an Overweight rating on the shares. While noting that the company reported Q3 results that missed expectations, the firm thinks expanding Revio utilization has potential to support upside to its consumable estimates and contends that NIH clarity could drive stronger instruments than it models.
Piper Sandler
Neutral
maintain
2025-08-11
Reason
Piper Sandler
Price Target
2025-08-11
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on PacBio to $1.50 from $1.25 following quarterly results. The firm keeps a Neutral rating on the shares.
Bernstein
Eve Burstein
Outperform
maintain
2025-08-08
Reason
Bernstein
Eve Burstein
Price Target
2025-08-08
maintain
Outperform
Reason
Bernstein analyst Eve Burstein raised the firm's price target on PacBio to $1.70 from $1.50 and keeps an Outperform rating on the shares. The firm notes PacBio reported 2Q25 results Thursday, with revenue of $39.8M 9% above consensus estimates of $36.6M. The company narrowed FY25 revenue guidance, but raised the gross margin guide and lowered the OpEx guide, Bernstein adds.
Barclays
Luke Sergott
Equal Weight
downgrade
$2
2025-06-25
Reason
Barclays
Luke Sergott
Price Target
$2
2025-06-25
downgrade
Equal Weight
Reason
Piper Sandler
Neutral
downgrade
$2
2025-05-15
Reason
Piper Sandler
Price Target
$2
2025-05-15
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on PacBio to $1.25 from $2 following quarterly results. The firm keeps a Neutral rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pacific Biosciences of California Inc (PACB.O) is -2.92, compared to its 5-year average forward P/E of -4.59. For a more detailed relative valuation and DCF analysis to assess Pacific Biosciences of California Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.59
Current PE
-2.92
Overvalued PE
34.50
Undervalued PE
-43.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.77
Current EV/EBITDA
-6.63
Overvalued EV/EBITDA
-0.43
Undervalued EV/EBITDA
-25.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
15.36
Current PS
1.61
Overvalued PS
30.04
Undervalued PS
0.68
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PACB.O News & Events

Events Timeline

(ET)
2025-11-05
16:37:04
PacBio Announces Q3 Earnings Per Share of 13 Cents, Below Consensus Estimate of 14 Cents
select
2025-11-05
09:12:37
PacBio Releases New Preprint on HiFi Sequencing
select
2025-11-04 (ET)
2025-11-04
09:11:39
PacBio assists Berry Genomics in obtaining sequencer approval in China
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-17NASDAQ.COM
PacBio Set to Present at Upcoming Investor Conferences

  • Upcoming Investor Conferences: PacBio will participate in several investor conferences, including the Wolfe Research Healthcare Conference and the Jefferies Global Healthcare Conference, highlighting its engagement with the healthcare investment community.

  • Financial Performance: For Q3 2025, PacBio reported total revenue of $38.4 million, a slight decrease from the previous year, but showed improvement in gross profit and a narrowed net loss, ending the quarter with $298.7 million in cash and investments.

  • Technological Advancements: The company introduced the SPRQ-Nx sequencing chemistry, which aims to reduce sequencing costs significantly, and received regulatory approval for its Sequel II CNDx system, enhancing its product offerings.

  • Market Positioning: PacBio's Revio and Vega systems are gaining traction in major studies, positioning the company competitively against short-read sequencing platforms, with recent sales contributing to instrument revenue of $11.3 million.

[object Object]
Preview
7.0
11-06SeekingAlpha
PacBio Updates 2025 Revenue Forecast to $155M-$160M Amid Record Consumable Sales and Increased Clinical Focus

  • Management Insights: Pacific Biosciences reported Q3 2025 revenue of $38.4 million, slightly below expectations, with strong consumable sales reaching an all-time high of $21.3 million. The company achieved a non-GAAP gross margin of 42%, the highest since 2022, and highlighted significant growth in the EMEA region.

  • Regulatory Milestone: The Sequel II CNDx system received Class III Medical Device Registration approval in China, marking a significant regulatory achievement for clinical-grade long-read sequencing technology.

  • Financial Outlook: The company narrowed its 2025 revenue guidance to $155 million–$160 million, anticipating a stronger Q4 driven by increased Revio placements and continued consumable strength, while also projecting cash and investments to exceed $270 million by year-end.

  • Challenges and Focus: Management acknowledged ongoing funding challenges, particularly in academic sectors, and delays in Vega system procurement in Europe. Despite these issues, they remain optimistic about clinical market penetration and the upcoming launch of SPRQ-Nx chemistry aimed at reducing genome sequencing costs.

[object Object]
Preview
5.0
11-05TipRanks
Cathie Wood Increases Investment in Veracyte Before Earnings Surprise, Reduces Biotech Portfolio

  • Portfolio Adjustments: Cathie Wood's Ark Invest has reduced its holdings in several biotech companies, including 10X Genomics and Crispr Therapeutics, indicating a shift away from volatile biotech stocks towards more stable growth sectors.

  • Investment in Veracyte: Ark made a significant investment in Veracyte, purchasing over 665,690 shares, which saw a strong earnings report that exceeded expectations, leading to a 16% stock surge.

  • Roku Stake Reduction: The firm also sold more than 1.1 million shares of Roku as part of a strategy to trim its portfolio, influenced by ongoing legal issues facing the company.

  • Analyst Consensus on Veracyte: Analysts maintain a Moderate Buy consensus on Veracyte, with an average 12-month price target suggesting a potential downside from the current price, reflecting cautious optimism about the stock's future performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pacific Biosciences of California Inc (PACB.O) stock price today?

The current price of PACB.O is 1.57 USD — it has decreased -2.48 % in the last trading day.

arrow icon

What is Pacific Biosciences of California Inc (PACB.O)'s business?

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

arrow icon

What is the price predicton of PACB.O Stock?

Wall Street analysts forecast PACB.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB.O is 2.30 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pacific Biosciences of California Inc (PACB.O)'s revenue for the last quarter?

Pacific Biosciences of California Inc revenue for the last quarter amounts to 38.44M USD, decreased -3.82 % YoY.

arrow icon

What is Pacific Biosciences of California Inc (PACB.O)'s earnings per share (EPS) for the last quarter?

Pacific Biosciences of California Inc. EPS for the last quarter amounts to -0.13 USD, decreased -40.91 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pacific Biosciences of California Inc (PACB.O)'s fundamentals?

The market is revising Downward the revenue expectations for Pacific Biosciences of California, Inc. (PACB) for FY2025, with the revenue forecasts being adjusted by -1.82% over the past three months. During the same period, the stock price has changed by 18.05%.
arrow icon

How many employees does Pacific Biosciences of California Inc (PACB.O). have?

Pacific Biosciences of California Inc (PACB.O) has 575 emplpoyees as of November 18 2025.

arrow icon

What is Pacific Biosciences of California Inc (PACB.O) market cap?

Today PACB.O has the market capitalization of 473.99M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free